Tau Monoclonal Antibody (HT7), Biotin | Invitrogen MN1000B product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

Tau Monoclonal Antibody (HT7), Biotin

catalog :

MN1000B

quantity :

50 µg

price :

US 395

clonality :

monoclonal

host :

mouse

conjugate :

biotin

clone name :

HT7

reactivity :

African green monkey, human, mouse, bovine

application :

western blot, ELISA, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - paraffin section, immunohistochemistry - free floating section, blocking or activating experiments

more info or order :

Invitrogen product webpage

citations: 88

Published Application/Species/Sample/Dilution	Reference
immunohistochemistry; human; 1:200; loading ...; fig 1c	Bennett R, Hu M, Fernandes A, Pérez Rando M, Robbins A, Kamath T, et al. Tau reduction in aged mice does not impact Microangiopathy. Acta Neuropathol Commun. 2020;8:137 pubmed publisher
ELISA; human	Liu W, Zhao L, Blackman B, Parmar M, Wong M, Woo T, et al. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice. J Neurosci. 2016;36:12425-12435 pubmed
immunohistochemistry - free floating section; mouse; 1:250; loading ...; fig 5a immunohistochemistry - paraffin section; mouse; 1:250; loading ...; fig 5a western blot; mouse; 1:2000; loading ...; fig 5b	Pajares M, Jiménez Moreno N, García Yagüe A, Escoll M, De Ceballos M, Van Leuven F, et al. Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes. Autophagy. 2016;12:1902-1916 pubmed
western blot; human; 1:2000	Xia D, Götz J. Premature lethality, hyperactivity, and aberrant phosphorylation in transgenic mice expressing a constitutively active form of Fyn. Front Mol Neurosci. 2014;7:40 pubmed publisher
western blot; mouse; 1:500	Shilling D, Müller M, Takano H, Mak D, Abel T, Coulter D, et al. Suppression of InsP3 receptor-mediated Ca2+ signaling alleviates mutant presenilin-linked familial Alzheimer's disease pathogenesis. J Neurosci. 2014;34:6910-23 pubmed publisher
immunohistochemistry; mouse; 1:400 ELISA; mouse; 1:1000	Castillo Carranza D, Sengupta U, Guerrero Muñoz M, Lasagna Reeves C, Gerson J, Singh G, et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci. 2014;34:4260-72 pubmed publisher
western blot; mouse; 1:200	di Meco A, Joshi Y, Pratico D. Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of Alzheimer's disease with plaques and tangles. Neurobiol Aging. 2014;35:1813-20 pubmed publisher
immunohistochemistry; mouse; 1:200	Choi B, Cho W, Kim J, Lee H, Chung C, Jeon W, et al. Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer's disease. Exp Mol Med. 2014;46:e75 pubmed publisher
immunohistochemistry; human western blot; human	Chabrier M, Cheng D, Castello N, Green K, LaFerla F. Synergistic effects of amyloid-beta and wild-type human tau on dendritic spine loss in a floxed double transgenic model of Alzheimer's disease. Neurobiol Dis. 2014;64:107-17 pubmed publisher
western blot; mouse; 1:1000	Orr M, Salinas A, Buffenstein R, Oddo S. Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology. Neurobiol Aging. 2014;35:1233-42 pubmed publisher
western blot; mouse; 1:1000	Yamada E, Respondek G, Müssner S, de Andrade A, Höllerhage M, Depienne C, et al. Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phosphorylation of tau in the brain of FTDP-17 transgenic mice. Exp Neurol. 2014;253:113-25 pubmed publisher
immunoprecipitation; mouse immunohistochemistry; mouse western blot; mouse	Borghgraef P, Menuet C, Theunis C, Louis J, Devijver H, Maurin H, et al. Increasing brain protein O-GlcNAc-ylation mitigates breathing defects and mortality of Tau.P301L mice. PLoS ONE. 2013;8:e84442 pubmed publisher
immunohistochemistry; mouse; 1:200	Hoffmann N, Dorostkar M, Blumenstock S, Goedert M, Herms J. Impaired plasticity of cortical dendritic spines in P301S tau transgenic mice. Acta Neuropathol Commun. 2013;1:82 pubmed publisher
immunohistochemistry; mouse; 1:1000 western blot; mouse; 1:1000	Rice R, Berchtold N, Cotman C, Green K. Age-related downregulation of the CaV3.1 T-type calcium channel as a mediator of amyloid beta production. Neurobiol Aging. 2014;35:1002-11 pubmed publisher
western blot; human; 1:5000	Baglietto Vargas D, Kitazawa M, Le E, Estrada Hernandez T, Rodriguez Ortiz C, Medeiros R, et al. Endogenous murine tau promotes neurofibrillary tangles in 3xTg-AD mice without affecting cognition. Neurobiol Dis. 2014;62:407-15 pubmed publisher
immunocytochemistry; mouse; 1:300 immunohistochemistry; mouse; 1:300	Pristerà A, Saraulli D, Farioli Vecchioli S, Strimpakos G, Costanzi M, Di Certo M, et al. Impact of N-tau on adult hippocampal neurogenesis, anxiety, and memory. Neurobiol Aging. 2013;34:2551-63 pubmed publisher
western blot; human	Ozdemir A, Rom I, Kovalevich J, Yen W, Adiga R, Dave R, et al. PINCH in the cellular stress response to tau-hyperphosphorylation. PLoS ONE. 2013;8:e58232 pubmed publisher
western blot; mouse	Nash K, Lee D, Hunt J, Morganti J, Selenica M, Moran P, et al. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiol Aging. 2013;34:1540-8 pubmed publisher
western blot; mouse; 1:5000	Baglietto Vargas D, Medeiros R, Martinez Coria H, LaFerla F, Green K. Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology. Biol Psychiatry. 2013;74:357-66 pubmed publisher
western blot; human; 1:40000	Kohler C, Dinekov M, Götz J. Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice. Neurobiol Aging. 2013;34:1369-79 pubmed publisher
immunohistochemistry; mouse; 1:1000	ATTAR A, Ripoli C, Riccardi E, Maiti P, Li Puma D, Liu T, et al. Protection of primary neurons and mouse brain from Alzheimer's pathology by molecular tweezers. Brain. 2012;135:3735-48 pubmed publisher
ELISA; human	Lund H, Cowburn R, Gustafsson E, Strömberg K, Svensson A, Dahllund L, et al. Tau-tubulin kinase 1 expression, phosphorylation and co-localization with phospho-Ser422 tau in the Alzheimer's disease brain. Brain Pathol. 2013;23:378-89 pubmed publisher
immunohistochemistry; human; 1:1000	Harris J, Koyama A, Maeda S, Ho K, Devidze N, Dubal D, et al. Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS ONE. 2012;7:e45881 pubmed publisher
immunohistochemistry; mouse; 1:200 western blot; mouse	Flunkert S, Hierzer M, Löffler T, Rabl R, Neddens J, Duller S, et al. Elevated levels of soluble total and hyperphosphorylated tau result in early behavioral deficits and distinct changes in brain pathology in a new tau transgenic mouse model. Neurodegener Dis. 2013;11:194-205 pubmed publisher
western blot; human; 1:2000	Deramecourt V, Lebert F, Maurage C, Fernandez Gomez F, Dujardin S, Colin M, et al. Clinical, neuropathological, and biochemical characterization of the novel tau mutation P332S. J Alzheimers Dis. 2012;31:741-9 pubmed publisher
western blot; human	Medeiros R, Kitazawa M, Chabrier M, Cheng D, Baglietto Vargas D, Kling A, et al. Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice. Am J Pathol. 2012;181:616-25 pubmed publisher
western blot; African green monkey	Matsushima T, Saito Y, Elliott J, Iijima Ando K, Nishimura M, Kimura N, et al. Membrane-microdomain localization of amyloid ?-precursor protein (APP) C-terminal fragments is regulated by phosphorylation of the cytoplasmic Thr668 residue. J Biol Chem. 2012;287:19715-24 pubmed publisher
ELISA; mouse	Zhang B, Carroll J, Trojanowski J, Yao Y, Iba M, Potuzak J, et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci. 2012;32:3601-11 pubmed publisher
immunohistochemistry; human; 1:4000	Clausen A, Xu X, Bi X, Baudry M. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline. J Alzheimers Dis. 2012;30:183-208 pubmed publisher
immunohistochemistry; mouse; 1:1000 western blot; mouse; 1:5000	de Calignon A, Polydoro M, Suarez Calvet M, William C, Adamowicz D, Kopeikina K, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73:685-97 pubmed publisher
western blot; human	Kawakami F, Yabata T, Ohta E, Maekawa T, Shimada N, Suzuki M, et al. LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS ONE. 2012;7:e30834 pubmed publisher
western blot; mouse; 1:2000	Burnouf S, Belarbi K, Troquier L, Derisbourg M, Demeyer D, Leboucher A, et al. Hippocampal BDNF expression in a tau transgenic mouse model. Curr Alzheimer Res. 2012;9:406-10 pubmed
western blot; human	Takahashi M, Chin Y, Nonaka T, Hasegawa M, Watanabe N, Arai T. Prolonged nitric oxide treatment induces tau aggregation in SH-SY5Y cells. Neurosci Lett. 2012;510:48-52 pubmed publisher
immunohistochemistry; human; 1:2000 western blot; human	Kitazawa M, Cheng D, Tsukamoto M, Koike M, Wes P, Vasilevko V, et al. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal ?-catenin pathway function in an Alzheimer's disease model. J Immunol. 2011;187:6539-49 pubmed publisher
immunohistochemistry; human	Saing T, Dick M, Nelson P, Kim R, Cribbs D, Head E. Frontal cortex neuropathology in dementia pugilistica. J Neurotrauma. 2012;29:1054-70 pubmed publisher
western blot; human; 1:1000	Khandelwal P, Dumanis S, Herman A, Rebeck G, Moussa C. Wild type and P301L mutant Tau promote neuro-inflammation and ?-Synuclein accumulation in lentiviral gene delivery models. Mol Cell Neurosci. 2012;49:44-53 pubmed publisher
immunohistochemistry; mouse; 1:500	Gong E, Park H, Kim M, Piao S, Lee E, Jo D, et al. Morin attenuates tau hyperphosphorylation by inhibiting GSK3Î². Neurobiol Dis. 2011;44:223-30 pubmed publisher
immunohistochemistry; mouse; 1:3000 western blot; mouse; 1:3000	Tang J, Mardini F, Caltagarone B, Garrity S, Li R, Bianchi S, et al. Anesthesia in presymptomatic Alzheimer's disease: a study using the triple-transgenic mouse model. Alzheimers Dement. 2011;7:521-531.e1 pubmed publisher
immunohistochemistry; human; 0.2 ug/mL	Tran H, LaFerla F, Holtzman D, Brody D. Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-? accumulation and independently accelerates the development of tau abnormalities. J Neurosci. 2011;31:9513-25 pubmed publisher
western blot; mouse; 1:5000	Medeiros R, Kitazawa M, Caccamo A, Baglietto Vargas D, Estrada Hernandez T, Cribbs D, et al. Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline. Am J Pathol. 2011;179:980-91 pubmed publisher
western blot; mouse	Silveyra M, García Ayllón M, de Barreda E, Small D, Martinez S, Avila J, et al. Altered expression of brain acetylcholinesterase in FTDP-17 human tau transgenic mice. Neurobiol Aging. 2012;33:624.e23-34 pubmed publisher
immunohistochemistry; human; 1:100	Kovacs G, Molnár K, Laszlo L, Strobel T, Botond G, Hönigschnabl S, et al. A peculiar constellation of tau pathology defines a subset of dementia in the elderly. Acta Neuropathol. 2011;122:205-22 pubmed publisher
immunohistochemistry; mouse	Barten D, Cadelina G, Hoque N, DeCarr L, Guss V, Yang L, et al. Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. J Alzheimers Dis. 2011;24 Suppl 2:127-41 pubmed publisher
western blot; mouse; 1:3,000	Koike M, Garcia F, Kitazawa M, Green K, LaFerla F. Long term changes in phospho-APP and tau aggregation in the 3xTg-AD mice following cerebral ischemia. Neurosci Lett. 2011;495:55-9 pubmed publisher
immunoprecipitation; human	Coffman K, Brodney M, Cook J, Lanyon L, Pandit J, Sakya S, et al. 6-amino-4-(pyrimidin-4-yl)pyridones: novel glycogen synthase kinase-3? inhibitors. Bioorg Med Chem Lett. 2011;21:1429-33 pubmed publisher
immunohistochemistry; human western blot; human	Ksiezak Reding H, Ho L, Santa Maria I, Díaz Ruiz C, Wang J, Pasinetti G. Ultrastructural alterations of Alzheimer's disease paired helical filaments by grape seed-derived polyphenols. Neurobiol Aging. 2012;33:1427-39 pubmed publisher
western blot; human	Van der Jeugd A, Ahmed T, Burnouf S, Belarbi K, Hamdame M, Grosjean M, et al. Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. Neurobiol Learn Mem. 2011;95:296-304 pubmed publisher
immunocytochemistry; human western blot; human	Sultan A, Nesslany F, Violet M, Bégard S, Loyens A, Talahari S, et al. Nuclear tau, a key player in neuronal DNA protection. J Biol Chem. 2011;286:4566-75 pubmed publisher
immunohistochemistry; mouse; 1:100	Bittner T, Fuhrmann M, Burgold S, Ochs S, Hoffmann N, Mitteregger G, et al. Multiple events lead to dendritic spine loss in triple transgenic Alzheimer's disease mice. PLoS ONE. 2010;5:e15477 pubmed publisher
immunohistochemistry; human; 1:3000 western blot; human; 1:3000	Medina D, Caccamo A, Oddo S. Methylene blue reduces a? levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 2011;21:140-9 pubmed publisher
immunohistochemistry; human; 1:200 western blot; human; 1:1000	Hamilton L, Aumont A, Julien C, Vadnais A, Calon F, Fernandes K. Widespread deficits in adult neurogenesis precede plaque and tangle formation in the 3xTg mouse model of Alzheimer's disease. Eur J Neurosci. 2010;32:905-20 pubmed publisher
immunohistochemistry; human; 1:200	Desai M, Mastrangelo M, Ryan D, Sudol K, Narrow W, Bowers W. Early oligodendrocyte/myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target. Am J Pathol. 2010;177:1422-35 pubmed publisher
immunohistochemistry; human	Larionov S, Wielgat P, Wang Y, Thal D, Neumann H. Spatially pathogenic forms of tau detected in Alzheimer's disease brain tissue by fluorescence lifetime-based Förster resonance energy transfer. J Neurosci Methods. 2010;192:127-37 pubmed publisher
immunohistochemistry; human western blot; human	Ittner L, Ke Y, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010;142:387-97 pubmed publisher
flow cytometry; human immunocytochemistry; human western blot; human	van Eersel J, Ke Y, Liu X, Delerue F, Kril J, Götz J, et al. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc Natl Acad Sci U S A. 2010;107:13888-93 pubmed publisher
western blot; human; 1:1000	Li Y, Duffy K, Ottinger M, Ray B, Bailey J, Holloway H, et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis. 2010;19:1205-19 pubmed publisher
western blot; human	Krupka N, Strappe P, Götz J, Ittner L. Gateway-compatible lentiviral transfer vectors for ubiquitin promoter driven expression of fluorescent fusion proteins. Plasmid. 2010;63:155-60 pubmed publisher
western blot; human; 1:5000	Martinez Coria H, Green K, Billings L, Kitazawa M, Albrecht M, Rammes G, et al. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol. 2010;176:870-80 pubmed publisher
immunocytochemistry; human; 1:200 western blot; human immunocytochemistry; mouse; 1:200 western blot; mouse	Vale C, Alonso E, Rubiolo J, Vieytes M, LaFerla F, Gimenez Llort L, et al. Profile for amyloid-beta and tau expression in primary cortical cultures from 3xTg-AD mice. Cell Mol Neurobiol. 2010;30:577-90 pubmed publisher
immunocytochemistry; human western blot; human	Campos Peña V, Tapia Ramírez J, Sanchez Torres C, Meraz Rios M. Pathological-like assembly of tau induced by a paired helical filament core expressed at the plasma membrane. J Alzheimers Dis. 2009;18:919-33 pubmed publisher
western blot; human	Nonaka T, Hasegawa M. A cellular model to monitor proteasome dysfunction by alpha-synuclein. Biochemistry. 2009;48:8014-22 pubmed publisher
western blot; human; 1:100 western blot; mouse; 1:100	Perreault S, Bousquet O, Lauzon M, Paiement J, Leclerc N. Increased association between rough endoplasmic reticulum membranes and mitochondria in transgenic mice that express P301L tau. J Neuropathol Exp Neurol. 2009;68:503-14 pubmed publisher
blocking or activating experiments; human western blot; human; 1:1000	Clavaguera F, Bolmont T, Crowther R, Abramowski D, Frank S, Probst A, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909-13 pubmed publisher
immunohistochemistry; mouse; 1:200	Mastrangelo M, Bowers W. Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neurosci. 2008;9:81 pubmed publisher
western blot; human	Tremblay C, Pilote M, Phivilay A, Emond V, Bennett D, Calon F. Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 2007;12:377-90 pubmed
immunohistochemistry; mouse western blot; mouse	Oddo S, Caccamo A, Cheng D, Jouleh B, Torp R, LaFerla F. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. J Neurochem. 2007;102:1053-63 pubmed
ELISA; human; 2 ug/ml	Yamamori H, Khatoon S, Grundke Iqbal I, Blennow K, Ewers M, Hampel H, et al. Tau in cerebrospinal fluid: a sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification. Neurosci Lett. 2007;418:186-9 pubmed
	Kashyap R, Balzano M, Lechat B, Lambaerts K, Egea Jimenez A, Lembo F, et al. Syntenin-knock out reduces exosome turnover and viral transduction. Sci Rep. 2021;11:4083 pubmed publisher
	Sandusky Beltran L, Kovalenko A, Placides D, Ratnasamy K, Ma C, Hunt J, et al. Aberrant AZIN2 and polyamine metabolism precipitates tau neuropathology. J Clin Invest. 2021;131: pubmed publisher
	Laversenne V, Nazeeruddin S, Källstig E, Colin P, Voize C, Schneider B. Anti-Aβ antibodies bound to neuritic plaques enhance microglia activity and mitigate tau pathology. Acta Neuropathol Commun. 2020;8:198 pubmed publisher
	Gratuze M, Leyns C, Sauerbeck A, St Pierre M, Xiong M, Kim N, et al. Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. J Clin Invest. 2020;130:4954-4968 pubmed publisher
	Sola M, Magrin C, Pedrioli G, Pinton S, Salvade A, Papin S, et al. Tau affects P53 function and cell fate during the DNA damage response. Commun Biol. 2020;3:245 pubmed publisher
	Lin Y, Rajamohamedsait H, Sandusky Beltran L, Gamallo Lana B, Mar A, Sigurdsson E. Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model. Front Aging Neurosci. 2019;11:377 pubmed publisher
	Gallardo G, Wong C, Ricardez S, Mann C, Lin K, Leyns C, et al. Targeting tauopathy with engineered tau-degrading intrabodies. Mol Neurodegener. 2019;14:38 pubmed publisher
	Shi Y, Manis M, Long J, Wang K, Sullivan P, Remolina Serrano J, et al. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J Exp Med. 2019;216:2546-2561 pubmed publisher
	Carlomagno Y, Chung D, Yue M, Kurti A, Avendano N, Castanedes Casey M, et al. Enhanced phosphorylation of T153 in soluble tau is a defining biochemical feature of the A152T tau risk variant. Acta Neuropathol Commun. 2019;7:10 pubmed publisher
	Zhao N, Liu C, Van Ingelgom A, Linares C, Kurti A, Knight J, et al. APOE ε2 is associated with increased tau pathology in primary tauopathy. Nat Commun. 2018;9:4388 pubmed publisher
	Eftekharzadeh B, Daigle J, Kapinos L, Coyne A, Schiantarelli J, Carlomagno Y, et al. Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease. Neuron. 2018;99:925-940.e7 pubmed publisher
	Wegmann S, Eftekharzadeh B, Tepper K, Zoltowska K, Bennett R, Dujardin S, et al. Tau protein liquid-liquid phase separation can initiate tau aggregation. EMBO J. 2018;37: pubmed publisher
	Gibbons G, Banks R, Kim B, Changolkar L, Riddle D, Leight S, et al. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies. J Neuropathol Exp Neurol. 2018;77:216-228 pubmed publisher
	Cuadrado A, Kügler S, Lastres Becker I. Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy. Redox Biol. 2018;14:522-534 pubmed publisher
	Leyns C, ULRICH J, Finn M, Stewart F, Koscal L, Remolina Serrano J, et al. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci U S A. 2017;114:11524-11529 pubmed publisher
	Shi Y, Yamada K, Liddelow S, Smith S, Zhao L, Luo W, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523-527 pubmed publisher
	Narasimhan S, Lee V. The use of mouse models to study cell-to-cell transmission of pathological tau. Methods Cell Biol. 2017;141:287-305 pubmed publisher
	Nobuhara C, DeVos S, Commins C, Wegmann S, Moore B, Roe A, et al. Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro. Am J Pathol. 2017;187:1399-1412 pubmed publisher
	Schoch K, DeVos S, Miller R, Chun S, Norrbom M, Wozniak D, et al. Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model. Neuron. 2016;90:941-7 pubmed publisher
	Luo W, Liu W, Hu X, Hanna M, Caravaca A, Paul S. Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci Rep. 2015;5:11161 pubmed publisher
	Santa Maria I, Díaz Ruiz C, Ksiezak Reding H, Chen A, Ho L, Wang J, et al. GSPE interferes with tau aggregation in vivo: implication for treating tauopathy. Neurobiol Aging. 2012;33:2072-81 pubmed publisher

product information

Product Type :

Antibody

Product Name :

Tau Monoclonal Antibody (HT7), Biotin

Catalog # :

MN1000B

Quantity :

50 µg

Price :

US 395

Clonality :

Monoclonal

Purity :

protein A

Host :

Mouse

Reactivity :

Bovine, Human

Applications :

ELISA: Assay-dependent, Immunohistochemistry: Assay-dependent

Species :

Bovine, Human

Clone :

HT7

Isotype :

IgG1, kappa

Storage :

4° C

Description :

Tau is a neuronal microtubule-associated protein found predominantly on axons. The function of Tau is to promote tubulin polymerization and stabilize microtubules. The C-terminus binds axonal microtubules while the N- terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton while the longer isoforms may preferentially play a role in its stabilization. In its hyper-phosphorylated form, Tau is the major component of paired helical filaments (PHF), the building block of neurofibrillary lesions in Alzheimer's diseases (AD) brain. Hyper-phosphorylation impairs the microtubule binding function of Tau, resulting in the destabilization of microtubules in AD brains, ultimately leading to the degeneration of the affected neurons. Numerous serine/threonine kinases phosphorylate Tau, including GSK-3beta, protein kinase A (PKA), cyclin-dependent kinase 5 (cdk5) and casein kinase II. Hyper-phosphorylated Tau is found in neurofibrillary lesions in a range and other central nervous system disorders such as Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.

Immunogen :

Purified human Tau, epitope human Tau between residue 159 and 163 (numbering according to human Tau40), corresponding to the amino acid sequence PPGQK.

Format :

Liquid

Applications w/Dilutions :

ELISA: Assay-dependent, Immunohistochemistry: Assay-dependent

Aliases :

AI413597; AW045860; DDPAC; FLJ31424; FTDP17; FTDP-17; G protein beta1/gamma2 subunit-interacting factor 1; map tau; Mapt; MAPTL; MGC138549; microtubule associated protein tau; microtubule-associated protein tau; microtubule-associated protein tau, isoform 4; microtubules; MSTD; Mtapt; MTBT1; MTBT2; Neurofibrillary tangle protein; neurofibrillary tangles; Neuronal Marker; paired helical filament-tau; PHFtau; PHF-tau; PPND; PPP1R103; protein phosphatase 1, regulatory subunit 103; pTau; RNPTAU; Tau; Tau microtubule-associated protein; tau protein; Tau-4; Tau5; Unknown (protein for MGC:134287)

more info or order :

Invitrogen product webpage